# Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients

> **NCT02314637** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 240 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Teneligliptin
- **DRUG:** Teneligliptin + Sulfonylurea

## Key facts

- **NCT ID:** NCT02314637
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02314637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02314637, "Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02314637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*